JG
DNA icon

Joel Greenblatt’s Ginkgo Bioworks DNA Stock Holding History

Joel Greenblatt’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-40,560
Closed -$542K – 1438
2024
Q2 		$542K Buy
40,560
+39,138
+2,752% +$1.17M 0.01% 1069
2024
Q1 		$66K Sell
1,422
-32,351
-96% -$1.67M ﹤0.01% 1347
2023
Q4 		$2.28M Sell
33,773
-14,719
-30% -$901K 0.04% 560
2023
Q3 		$3.51M Buy
48,492
+9,797
+25% +$783K 0.07% 386
2023
Q2 		$2.88M Buy
38,695
+29,925
+341% +$1.77M 0.06% 437
2023
Q1 		$467K Sell
8,770
-16,234
-65% -$1.03M 0.01% 991
2022
Q4 		$1.69M Sell
25,004
-1,180
-5% -$109K 0.05% 481
2022
Q3 		$3.27M Buy
26,184
+7,141
+37% +$851K 0.1% 243
2022
Q2 		$1.81M Buy
19,043
+18,595
+4,151% +$2.27M 0.06% 402
2022
Q1 		$72K Buy
+448
New +$87.2K ﹤0.01% 1109

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Joel Greenblatt's DNA Position: Q3 2024 in Review

Joel Greenblatt sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 40,560 shares — an estimated $542K sold.

Joel Greenblatt first reported a position in DNA in Q1 2022 and held it in 10 quarters. The position peaked at $3.51M in Q3 2023. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Joel Greenblatt reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Joel Greenblatt sold 40,560 Ginkgo Bioworks shares in Q3 2024, an estimated $542K.
  • Joel Greenblatt first reported a position in Ginkgo Bioworks in Q1 2022 and held it in 10 quarters.
  • Joel Greenblatt's Ginkgo Bioworks position peaked at $3.51M in Q3 2023.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Gotham Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.